Bright Minds Biosciences Inc.

NasdaqCM:DRUG Stock Report

Market Cap: US$584.5m

Bright Minds Biosciences Past Earnings Performance

Past criteria checks 0/6

Bright Minds Biosciences's earnings have been declining at an average annual rate of -7.5%, while the Biotechs industry saw earnings growing at 36.2% annually.

Key information

-7.48%

Earnings growth rate

29.17%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-8.87%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Jan 07

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Summary Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epilepsy and DEE cohorts, respectively. Multiple 2026 catalysts include additional phase 2 data, phase 3 trial initiation, and a phase 2 PWS study for BMB-101. Recent $100M financing and ATM program extend the runway, but further capital raises may be needed as clinical programs advance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Summary We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2 2025. The company has a decent balance sheet, with roughly $40.3 million in cash. It may need to raise capital by mid-2026 or earlier as R&D expenses increase. A strategic partnership or acquisition could enhance value if the company's pipeline proves successful in clinic. Read the full article on Seeking Alpha
Seeking Alpha • Aug 18

Bright Minds says no material events fueled rally

After over 100% surge in its share price, Canadian biotech Bright Minds Biosciences (NASDAQ:DRUG) (OTCQB:BMBIF) announced Thursday that the company is unaware of any material events or undisclosed corporate actions that caused today’s rally. The company announced this in response to a request by the Investment Industry Regulatory Organization of Canada, which has sought its comments on its recent trading activity. DRUG, a pre-clinical biosciences company, added ~121% during regular trading on above-average volumes. About 119.5 company shares changed hands, compared to the 65-day average volume of ~58.3K. “The Company is not aware of any material, undisclosed corporate developments and has no material change in its business or affairs that has not been publicly disclosed that would account for the recent increase in volume or price,” Bright Minds (DRUG) said. DRUG shares have lost ~3.2% in post-market trading. Read Seeking Alpha’s “On the Move” section to monitor shares with the biggest moves.

Revenue & Expenses Breakdown

How Bright Minds Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:DRUG Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-27526
31 Dec 250-20316
30 Sep 250-12311
30 Jun 250-927
31 Mar 250-323
31 Dec 240-121
30 Sep 240-311
30 Jun 240-422
31 Mar 240-523
31 Dec 230-725
30 Sep 230-725
30 Jun 230-926
31 Mar 230-1027
31 Dec 220-12210
30 Sep 220-15312
30 Jun 220-15312
31 Mar 220-16313
31 Dec 210-13310
30 Sep 210-926
30 Jun 210-624
31 Mar 210-312
31 Dec 200-101
30 Sep 200000

Quality Earnings: DRUG is currently unprofitable.

Growing Profit Margin: DRUG is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DRUG is unprofitable, and losses have increased over the past 5 years at a rate of 7.5% per year.

Accelerating Growth: Unable to compare DRUG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DRUG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: DRUG has a negative Return on Equity (-8.87%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 17:07
End of Day Share Price 2026/06/16 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bright Minds Biosciences Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Charles MooreBaird
Joel BeattyBaird